1. Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018; 20:1721–1731. PMID:
30191649.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017; 263:343–351. PMID:
28624099.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019; 115:844–853. PMID:
30715247.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014; 15:1063–1093. PMID:
25239940.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37:2768–2801. PMID:
27567406.
6. Kim H, Chung WB, Cho KI, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound. 2018; 26:1–25. PMID:
29629020.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Youn JC, Han S, Ryu KH. Temporal trends of hospitalized patients with heart failure in Korea. Korean Circ J. 2017; 47:16–24. PMID:
28154584.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. Korean J Intern Med. 2019; 34:11–43. PMID:
30612416.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Kim DY, Youn JC, Park MS, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: a 10-year multicenter cohort study. J Cardiol. 2019; 74:175–181. PMID:
30827728.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Kim KJ, Cho HJ, Kim MS, et al. Focused update of 2016 Korean Society of Heart failure guidelines for the management of chronic heart failure. Int J Heart Fail. 2019; 1:4–24.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Lee JH, Kim MS, Yoo BS, et al. KSHF guidelines for the management of acute heart failure: part II. Treatment of acute heart failure. Korean Circ J. 2019; 49:22–45. PMID:
30637994.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Stewart Coats AJ. Common co-morbidities in heart failure – diabetes, functional mitral regurgitation and sleep apnoea. Int J Heart Fail. 2019; 1:25–41.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Lee HY, Oh BH. Paradigm shifts of heart failure therapy: do we need another paradigm? Int J Heart Fail. 2020.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Uhm JS, Chung WB, Yoon JS, Oh YS, Youn HJ. Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. Clin Hypertens. 2014; 20:8. PMID:
26909195.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med. 2016; 31:625–633. PMID:
27378126.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Chung WB, Yi JE, Jin JY, et al. Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. J Breast Cancer. 2013; 16:178–183. PMID:
23843850.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Gripp EA, Oliveira GE, Feijó LA, Garcia MI, Xavier SS, Sousa AS. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment. Arq Bras Cardiol. 2018; 110:140–150. PMID:
29561992.
18. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017; 35:893–911. PMID:
27918725.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Virizuela JA, García AM, de Las Peñas R, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol. 2019; 21:94–105. PMID:
30627982.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31:171–190. PMID:
31959335.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin Adjuvant study cardiac marker substudy. J Clin Oncol. 2017; 35:878–884. PMID:
28199174.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Michel L, Mincu RI, Mahabadi AA, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020; 22:350–361. PMID:
31721381.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020; 7:26. PMID:
32258060.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018; 10:S4282–95. PMID:
30701097.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Kittiwarawut A, Vorasettakarnkij Y, Tanasanvimon S, Manasnayakorn S, Sriuranpong V. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. Asia Pac J Clin Oncol. 2013; 9:155–161. PMID:
22897825.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Negishi T, Miyazaki S, Negishi K. Echocardiography and cardio-oncology. Heart Lung Circ. 2019; 28:1331–1338. PMID:
31230869.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of immune therapy. Cardiol Clin. 2019; 37:385–397. PMID:
31587780.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378:158–168. PMID:
29320654.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Ganatra S, Carver JR, Hayek SS, et al. Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives. J Am Coll Cardiol. 2019; 74:3153–3163. PMID:
31856973.
30. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016; 375:1749–1755. PMID:
27806233.
31. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018; 71:1755–1764. PMID:
29567210.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391:933.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018; 19:e447–58. PMID:
30191849.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019; 140:80–91. PMID:
31390169.
35. Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017; 136:2085–2087. PMID:
29158217.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018; 19:1579–1589. PMID:
30442497.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Obstfeld AE, Frey NV, Mansfield K, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood. 2017; 130:2569–2572. PMID:
29074500.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377:2531–2544. PMID:
29226797.
39. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378:439–448. PMID:
29385370.
40. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380:45–56. PMID:
30501490.
41. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020; 9:e013757. PMID:
31960755.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007; 101:248–257. PMID:
17569889.
43. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003; 9:1477–1483. PMID:
14595408.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291:319–322. PMID:
11209085.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Lichtman AH. The heart of the matter: protection of the myocardium from T cells. J Autoimmun. 2013; 45:90–96. PMID:
23810579.
![crossref](/image/icon/bnr_ref_cross.gif)
46. Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012; 188:4876–4884. PMID:
22491251.
![crossref](/image/icon/bnr_ref_cross.gif)
47. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004; 363:203–209. PMID:
14738793.
![crossref](/image/icon/bnr_ref_cross.gif)
48. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122:863–871. PMID:
23770775.
![crossref](/image/icon/bnr_ref_cross.gif)
49. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018; 36:1714–1768. PMID:
29442540.
50. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009; 53:1475–1487. PMID:
19389557.
![crossref](/image/icon/bnr_ref_cross.gif)
51. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018; 72:3158–3176. PMID:
30545455.
52. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004; 109:1250–1258. PMID:
14993139.
![crossref](/image/icon/bnr_ref_cross.gif)
53. Abdel-Aty H, Boyé P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005; 45:1815–1822. PMID:
15936612.
![crossref](/image/icon/bnr_ref_cross.gif)
54. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25:625–638. PMID:
30592986.
![crossref](/image/icon/bnr_ref_cross.gif)
55. Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018; 23:943–947. PMID:
29622697.
![crossref](/image/icon/bnr_ref_cross.gif)
56. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6:224ra25.